Regeneron and Sanofi’s arthritis drug shows no benefit in non-critical COVID-19 patients

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is collaborating with Sanofi SA (EPA: SAN) to test Kevzara (arthritis drug) as a potential treatment for COVID-19. In a joint statement on Monday, both companies highlighted that the drug failed to show promising results in patients with mild or moderate symptoms of respiratory disease. Kevzara, the companies added, will now be tested only in the critical cases of COVID-19.